Perceive Pharma Attracts $15M Series A Financing to Advance Ophthalmic Neuroprotection
- Editor
- Feb 18
- 1 min read
Whats Happening:
Perceive Pharma, a pharmaceutical company focused on developing novel small molecule therapeutics in ophthalmology, has secured $15 million in Series A funding. The investment will be used to advance the company's lead glaucoma program to clinical readiness and support the development of neuroprotective therapies for other ophthalmic diseases.
Key Moves:
Perceive Pharma closes $15M Series A funding round
Dr. Carol Gallagher joins Perceive Pharma's Board as an independent Director
Funding to advance lead glaucoma program and other neuroprotective therapies
By The Numbers:
$15 million raised in Series A funding
Over 1.5 million Americans have glaucoma that continues to progress
Perceive Pharma's lead therapeutic candidate is PBI-671
Key Quotes:
"We look forward to working with our syndicate partners as Perceive Pharma continues to build compelling preclinical evidence of ophthalmic neuroprotection in key models of glaucoma." - Cameron Wheeler, Partner at Deerfield Management
"The deep science underlying the identification of Perceive's targets differentiates its programs and provides promise for new, transformative treatments for sight-saving therapies." - K. Angela Macfarlane, CEO
"I am delighted to join the Board of Perceive Pharma and to support this committed and experienced team working on first-in-class neuroprotective drugs." - Dr. Carol Gallagher
Bottom Line:
Perceive Pharma's successful Series A funding round positions the company to advance its innovative neuroprotective therapies for glaucoma and other ophthalmic diseases. With a focus on addressing unmet needs in vision loss prevention, particularly for patients with normal intraocular pressure, Perceive Pharma aims to develop transformative treatments that could benefit millions of people worldwide.
Hozzászólások